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Introduction: Administration of bone marrow mesenchymal stem cells (MSCs) or secreted microvesicles improves
recovery from acute kidney injury (AKI). However, the potential roles and mechanisms are not well understood. In
the current study, we focused on the protective effect of exosomes derived from human umbilical cord
mesenchymal stem cells (hucMSC-ex) on cisplatin-induced nephrotoxicity in vivo and in vitro.
Methods: We constructed cisplatin-induced AKI rat models. At 24 h after treatment with cisplatin, hucMSC-ex were
injected into the kidneys via the renal capsule; human lung fibroblast (HFL-1)-secreted exosomes (HFL-1-ex) were
used as controls. All animals were killed at day 5 after administration of cisplatin. Renal function, histological
changes, tubular apoptosis and proliferation, and degree of oxidative stress were evaluated. In vitro, rat renal tubular
epithelial (NRK-52E) cells were treated with or without cisplatin and after 6 h treated with or without exosomes.
Cells continued to be cultured for 24 h, and were then harvested for western blotting, apoptosis and detection of
degree of oxidative stress.
Results: After administration of cisplatin, there was an increase in blood urea nitrogen (BUN) and creatinine (Cr)
levels, apoptosis, necrosis of proximal kidney tubules and formation of abundant tubular protein casts and oxidative
stress in rats. Cisplatin-induced AKI rats treated with hucMSC-ex, however, showed a significant reduction in all the
above indexes. In vitro, treatment with cisplatin alone in NRK-52E cells resulted in an increase in the number of
apoptotic cells, oxidative stress and activation of the p38 mitogen-activated protein kinase (p38MAPK) pathway
followed by a rise in the expression of caspase 3, and a decrease in cell multiplication, while those results were
reversed in the hucMSCs-ex-treated group. Furthermore, it was observed that hucMSC-ex promoted cell
proliferation by activation of the extracellular-signal-regulated kinase (ERK)1/2 pathway.
Conclusions: The results in the present study indicate that hucMSC-ex can repair cisplatin-induced AKI in rats and
NRK-52E cell injury by ameliorating oxidative stress and cell apoptosis, promoting cell proliferation in vivo and
in vitro. This suggests that hucMSC-ex could be exploited as a potential therapeutic tool in cisplatin-induced
nephrotoxicity.
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Previous studies have shown that mesenchymal stem
cells (MSCs) from different sources, including human
bone marrow, cord blood, embryo and fetal membranes
can be applied in tissue repair, such as promoting reco-
very from acute kidney injury (AKI) induced by various
causes [1-4]. Similarly, our laboratory has demonstrated
that MSCs derived from human umbilical cord and rat
bone marrow mesenchymal stem cells can ameliorate
ischemia/reperfusion-induced AKI and mouse hepatic
injury [5-8]. Moreover, MSCs have been used in clinical
trials [9,10]. Recently, microvesicles (MVs) derived from
MSCs have been widely applied to experimental
research, including AKI. Some studies have demon-
strated that microvesicles released by human bone mar-
row MSCs contribute to repairing AKI induced by
glycerol and ischemia-reperfusion [11,12] and improved
survival in a lethal model of AKI induced by cisplatin in
severe combined immunodeficiency (SCID) mice [13].
Exosomes are microvesicles of multivesicular bodies
(MVBs) released from various cells into the extracellular
space when intracellular MVBs fuse with the plasma
membrane of the cell. Consequently, exosomes are
present in cell culture supernatants. Exosomes are com-
posed of a lipid bilayer, and contain proteins, mRNA
and miRNA [14,15]. Previous research has indicated that
exosomes play a biological role mainly in transmission
of proteins, mRNA and miRNA. CD9, CD63 and CD81
have been used as characteristic markers of exosomes
[15-17]. In view of these findings, more and more re-
search has been conducted with the aim of investigating
the functions of exosomes. The effect of exosomes on
AKI, hepatic injury and myocardial ischemia/reperfusion
injury has been demonstrated previously [11-13,18,19].
Cisplatin, as an anticancer drug, is often used to in-
duce an animal model of AKI [1,13]. The mechanism of
cisplatin renal toxicity is not fully understood; the main
reason for AKI occurrence may be renal tubular apop-
tosis, and the increase of lipid peroxidation and reactive
oxygen species (ROS) in the kidney, leading to kidney
oxidative damage and renal cell death. At the same time,
oxidative damage is one of the triggers for renal cell
apoptosis [20-22]. It has also been reported that antioxi-
dant stress pathways are stimulated by mesenchymal
stromal cells in renal repair after ischemia-reperfusion
injury [23]. Thus, we suggest exosomes derived from
MSCs may ameliorate AKI caused by antioxidant stress
pathways.
Although exosomes derived from bone marrow mes-
enchymal stem cells have been successfully applied in
improving survival in a lethal model of AKI induced by
cisplatin in SCID mice [13], the mechanism and the pro-
tective effect of exosomes in an immunocompetent
model are unclear. Moreover, the therapeutic potentialof exosomes derived from human umbilical cord mesen-
chymal stem cells (hucMSC-ex) on kidney injury has not
been reported so far.
Based on previous studies, the aim of the present study
was to investigate the effect of hucMSC-ex on cisplatin-
induced AKI. Our findings suggest that exosomes released
from hucMSCs could suppress cisplatin-induced AKI and
NRK-52E cell injury by improving oxidative stress and cell
apoptosis, promoting cell proliferation in vivo and in vitro.
Methods
Isolation and characterization of hucMSCs
All experiment protocols were approved by the medical
ethics committee of Jiangsu University (2012258). Fresh
umbilical cords were obtained from consenting mothers,
and processed within 6 h. HucMSCs were isolated as
previously described [24]. All cords were cultured in low
glucose Dulbecco’s modified Eagle’s medium (LG-DMEM)
containing 10% fetal bovine serum (FBS; Shanghai ExCell
Biology, China) and 1% penicillin and streptomycin at 37°C
with 5% CO2. Medium was replaced every 3 days after ini-
tial plating. When confluence reached 80%, the cells were
passaged into new flasks for further expansion. As control
cells, human lung fibroblasts (HFL-1; Cell Bank, Type Cul-
ture Collection Committee, Chinese Academy of Sciences)
were cultured with minimal essential medium alpha
(MEM-a) containing 15% FBS.
To detect the typical markers of different passages of
hucMSCs, flow cytometric analysis was performed
using the following fluorescein isothiocyanate (FITC)-
conjugated or phycoerythrin (PE)-conjugated anti-
bodies: CD13, CD29, CD44, CD90, CD105, human
leukocyte antigen (HLA)-I, CD34, CD45, and HLA-DR
(Becton Dickinson, San Jose, CA, USA). Mouse PE-
IgG1 and FITC-IgG1 isotypic immunoglobulins were
used as isotype controls.
To determine the multidirectional differentiation po-
tential of hucMSCs, the cells of passage 2 were seeded
into six-well plates at 1 × 105 cells per well. The next
day, the medium was changed to osteogenic medium
(0.1 μM dexamethasone, 10 μM β-glycerophosphate,
50 μM ascorbate-phosphate) and adipogenic medium
(Cyagen, Guangzhou, China). The medium was replaced
every 3 days. After 2 weeks, osteogenic differentiation of
hucMSCs was examined by neutrophil alkaline phos-
phatase (NAP) staining according to the manufacturer’s
protocol (SUNBIO, Shanghai, China). At 3 weeks later,
adipocytes were stained with Oil-Red-O staining.
Isolation and characterization of exosomes derived from
hucMSCs and HFL-1
HucMSCs and HFL-1 were cultured in serum-free
medium. After 48 h, cell culture media were collected and
density gradient centrifugations performed. Exosomes
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tants were centrifuged at several times, and then passed
through a 0.22-μm filter. Final exosomes were obtained
and stored at −70°C. The morphology of the collected
exosomes was observed by transmission electron micros-
copy (FEI Tecnai 12, Philips, The Netherlands). The CD9
(Bioworld, Louis Park, MN, USA), CD63 (Bioworld), and
CD81 (Epitomics, Burlingame, USA) molecules, fre-
quently located on the surface of exosomes, were analyzed
by western blotting. As described above, after hucMSCs
were cultured in media for 48 h, the conditioned media
(hucMSC-CM) was collected for the following experiment
in vivo. Exosome-depleted hucMSC-conditioned media
(non-hucMSC-ex) was also gathered for use in the rat
model of AKI.
Rat model of AKI
Adult female Sprague–Dawley rats (weighing 220 ± 20 g)
were purchased from the Animal Centre of Chinese
Academy of Sciences (Shanghai, China), and housed in
a specific pathogen-free animal facility under constant
temperature and humidity, and with a 12 h/12 h light/
dark cycle with sufficient qualified food and water. All
protocols and surgical procedures were approved by
the Institutional Animal Care Committee of Jiangsu
University.
To evaluate whether the exosomes derived from
hucMSCs could repair AKI but not other non-MSC cells
or MSC-secreted other cells except MSC, animals were
divided into six groups of six rats each, treated as fol-
lows. (1) Normal group (no cisplatin treatment). (2)
Phosphate-buffered saline (PBS) group: intraperitoneal
injection of a single dose of 6 mg/kg cisplatin. Cisplatin
(Dezhou Pharmaceutical, Shandong, China) was dissolved
in 0.9% saline. After 24 h, both kidneys in one rat received
a renal capsule injection of PBS. (3) hucMSC-ex group: 24
h after cisplatin administration, both kidneys in one rat re-
ceived a renal capsule injection of 200 μg exosomes from
hucMSCs. (4) hucMSC-CM group: after cisplatin treat-
ment for 24 h, rats received a renal capsule injection of
equal volumes of hucMSC-CM with hucMSC-ex. (5)
Non-hucMSC-ex group: after 24 h of cisplatin adminis-
tration, rats were given a renal capsule injection of
exosome-depleted hucMSC-conditioned media. (6)
HFL-1-ex group: 24 h after cisplatin treatment, rats re-
ceived a renal capsule injection of 200 μg exosomes
from HFL-1 to both kidneys.
Blood samples were collected from the rats via the tail
vein every day and centrifuged at 900 g for 15 minutes.
Then the serum was separated and stored at −70°C until
assayed. Rats were killed at day 5 after administration of
cisplatin; both kidneys were immediately excised and cut
into two coronal sections each. Two pieces of kidney were
fixed in 4% paraformaldehyde at room temperature, theothers were stored at −70°C. The blood urea nitrogen
(BUN) and creatinine (Cr) levels were determined by a
Biochemistry Autoanalyzer (Olympus, Tokyo, Japan).Location of hucMSC-ex in AKI kidney
To investigate whether exosomes could incorporate into
tubular epithelial cells, immunofluorescence was used. First,
we incubated exosomes and CM-Dil dye (Molecular
Probes, Eugene, OR, USA) together for 30 minutes at 37°C.
The CM-Dil dye-labeled exosomes were injected into the
AKI kidneys via the renal capsule, with unlabeled exosomes
used as a control. After 24 h, fresh kidney tissues were
removed for frozen sectioning. Then, frozen sections
were blocked using 5% bovine serum albumin (BSA) for
20 minutes. The sections were then incubated with
cytokeratin 19 antibody (Bioworld) at 37°C for 1 h.
After washing three times, green fluorescent anti-rabbit
antibody was used as secondary antibody. Finally,
Hoechst 33342 dye (Sigma Saint Louis, USA) was
added to the slices. Cytokeratin 19 antibody was used
for staining the cytoplasm of tubular epithelial cells and
Hoechst 33342 dye was used for nuclei staining.In vitro experiments
NRK-52E cells were purchased from Cell Bank, and
maintained in DMEM containing 10% newborn calf
serum (NBS; Gibco, Grand Island, USA) at 37°C with 5%
CO2. For in vitro treatments, NRK-52E cells were seeded
in six-well plates at 1 × 105 cells per well. At approxi-
mately 70% confluence, the control and cisplatin groups
were grown with or without 5 μM cisplatin for 6 h, then
the control and cisplatin groups were changed to fresh
medium. In the other two groups, after NRK-52E cells
were treated with 5 μM cisplatin for 6 h the culture solu-
tions were changed to 1 mL fresh medium with 160 μg/mL
exosomes derived from hucMSCs or HFL-1, respectively.
After 24 h, cells were fixed in 4% paraformaldehyde for
histologic staining or were collected for protein extraction,
and cell suspensions were collected to detect glutathione
(GSH) and malondialdehyde (MDA). In order to determine
whether hucMSC-ex promote cell proliferation through ac-
tivation of the extracellular-signal-regulated kinase (ERK)1/
2 pathway, cisplatin-treated NRK-52E cells were cultured in
fresh medium containing 160 μg/mL hucMSC-ex and 15 μM
U0126 (Promega, Wisconsin, USA); 24 h later, cells were col-
lected for protein detection.H&E staining
To detect the injury of kidney tubules, the kidneys were
fixed in 4% paraformaldehyde (pH 7.4) gradually
dehydrated, embedded in paraffin, cut into 4-μM sections
and stained with H&E stain.
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dUTP-biotin nick-end labeling (TUNEL) assay
Tissue slices underwent deparaffination and dehydration,
then renal tubular cell apoptosis was measured by the
TUNEL assay using an in situ cell apoptosis detection
kit (Boster, Wuhan, China) according to the manufac-
turer’s instructions.
Immunohistochemistry
Immunohistochemistry was used for detection of prolifer-
ating cell nuclear antigen (PCNA) and the renal oxidative
stress product 8-hydroxy-2′-deoxyguanosine (8-OHdG)
in vivo and in vitro. The kidney tissue slices underwent
deparaffination and dehydration, and were then immersed
in 30% hydrogen peroxide for 10 minutes to block en-
dogenous peroxidase and antigen retrieval for 10 minutes
in 0.01 M citrate buffer (pH 6.0) in turn. Then, sections
were incubated with PCNA antibody (Bioworld) and 8-
OHdG antibody (10 μg/mL, Japan Institute for Control of
Aging, Shizuoka, Japan) at 37°C for 1 h. Sections were
washed with PBS three times and incubated with
biotinylated goat anti-rabbit or anti-mouse IgG (Bostar,
Wuhan, China) at 37°C for 20 minutes followed by
streptavidin-biotin complex (SABC) for 20 minutes. The
antibody binding sites in the tissue slices were visualized
with 3,3′-diaminobenzidine (DAB), and counterstained
with hematoxylin. In vitro, the NRK-52E cells treated in
different ways were fixed in 4% paraformaldehyde for 30
minutes. After washing three times with PBS, cells were
incubated with 8-OHdG antibody at 37°C for 1 h, and in-
cubated with a secondary antibody for 20 minutes. Cells
were visualized with diaminobenzidine substrate and
counterstained with hematoxylin. The morphological tis-
sue and cell sections were evaluated by high-power light
microscopy examination (Nikon, Tokyo, Japan).
Mitochondrial membrane potential assay
A mitochondrial membrane potential assay kit with JC-1
staining solution (Beyotime, Nantong, China) was used
to detect early apoptosis. After NRK-52E cells were
treated in six well plates as described above, the medium
was changed for 1 mL fresh medium with 1 mL JC-1
(5 μg/mL) and cells incubated at 37°C for 20 minutes then
washed twice with JC-1 staining solution (1 μg/mL). Im-
ages were obtained by fluorescent microscopy and ana-
lyzed for green and red fluorescence. Mitochondrial
membrane potential depolarization was expressed by an
increase in the green/red fluorescence intensity ratio.
Measurement of GSH and MDA
In vivo, frozen kidney tissues were thawed, weighed and
grinded in homogenate medium (pH 7.4, 0.01 mol/L
Tris–HCl, 0.0001 mol/L ethylenediaminetetra-acetic acid
(EDTA)-Na2, 0.01 mol/L sucrose, 0.8% NaCl solution).Prepared 10% homogenate was centrifuged at 400 g, 10
minutes. In vitro, cells were collected and ground in
PBS. The total protein concentration from kidney tissues
or cultured cells was determined using the BCA assay
kit (Pierce, USA). Commercial assay kits used to deter-
mine GSH and MDA were purchased from Jiancheng
Bioengineering Institute (Nanjing, China). All the proce-
dures were performed according to the manufacturer’s
instructions.
Western blotting analysis
Kidney tissues and cells were lysed in radioimmunopre-
cipitation assay (RIPA) buffer (150 mM NaCl, 1 mM
ethylene glycol tetra-acetic acid (EGTA), 0.1% SDS, 1 mM
NaF, 1 mM Na3VO4, 1 mg/mL aprotinin, and 1 mg/mL
leupeptin in 10 mM Tris, pH 7.4) containing 1 mM
phenylmethanesulfonyl fluoride (PMSF). The protein con-
centration of each sample was determined using the BCA
assay kit. A total of 150 μg protein were electrophoresed
on 12% SDS-polyacrylamide gels, which were transferred
to polyvinylidene fluoride membranes, blocked with 5%
skim milk for 1 h and then blotted against primary
antibodies at 4°C overnight. Primary antibodies were
as follows: glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Kangchen Bio-tech, Shanghai, China), B cell
lymphoma 2 (Bcl-2) protein (Santa Cruz, Minneapolis,
USA), Bcl-2-associated X protein (Bax) (Bioworld), p-ERK
(Santa Cruz), ERK (Santa Cruz), phosphorylated p38
mitogen-activated protein kinase (p-p38MAPK) (Santa
Cruz) and p38MAPK (Santa Cruz), caspase 3 (Bioworld).
After this, the membrane was washed three times with
Tris-buffered saline/Tween (TBST) and incubated in
goat anti-rabbit or mouse antibodies (Bioworld) for 1 h
at 37°C. Western blotting detection was performed
using Luminata™ crescendo western horseradish perox-
idase (HRP) substrate (Millipore, Billerica, MA, USA).
Statistical analysis
All data were shown as means ± standard deviation
(SD). The statistically significant differences between
groups were assessed by analysis of variance (ANOVA)
with two-way classification, or ANOVA with Student-
Newman-Keuls multicomparison test using Prism soft-
ware (GraphPad, San Diego, USA). A P value of <0.05
was considered significant.
Results
Typical features of hucMSCs and hucMSC-ex
Fluorescence-activated cell sorting (FACS) analysis dem-
onstrated that hucMSCs expressed high levels of CD13,
CD29, CD44, CD90, CD105, and HLA-I, but were nega-
tive for CD34, CD45 and HLA-DR (Figure 1A). The
hucMSCs we obtained had the typical markers of MSCs.
After osteogenic and adipogenic medium induction,
Figure 1 Characterization of human umbilical cord mesenchymal stem cells (hucMSCs) and hucMSC-derived exosomes (hucMSC-ex).
(A) Flow cytometry analyses of phenotypic markers of hucMSCs; different passages of hucMSCs showed similar results. HucMSCs were positive for
CD13, CD29, CD44, CD90, CD105 and human leukocyte antigen (HLA)-I, and negative for CD34, CD45 and HLA-DR. (B) Cell lineage induced
differentiation. Control cells were grown in regular medium; there were no positive cells in the cell lineage differentiation. Osteogenic
differentiation of hucMSCs was shown by neutrophil alkaline phosphatase (NAP) staining; most hucMSCs were alkaline phosphatase positive.
Adipogenic differentiation was analyzed by Oil-Red-O staining. After induction, hucMSCs formed numerous Oil-Red-O-positive lipid droplets
(shown at original magnification, × 100). Scale bars: 100 μm. (C) Representative micrographs of transmission electron microscopy of purified
hucMSC-ex and human lung fibroblast secreted exosomes (HFL-1-ex), showing a spheroid shape. The scale bar represents 100 nm. (D) Western
blotting results indicated the positive expression of CD9, CD63 and CD81 proteins in exosomes derived from hucMSCs and HFL-1 cells.
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and showed numerous Oil-Red-O-positive lipid droplets
(Figure 1B, induction). Non-induced cultures did not show
spontaneous osteoblast or adipocyte formation (Figure 1B,
control). These results suggest that hucMSCs have the
ability to differentiate into adipocytes and osteocytes.
Transmission electron microscopy showed the spheroid
morphology of exosomes derived from hucMSCs and con-
firmed their size as 40 to 100 nm. HFL-1-releasedexosomes showed similar results (Figure 1C). Western
blotting analyses indicated that hucMSC-ex and HFL-1-ex
expressed exosomal markers such as CD9, CD63 and CD
81 protein (Figure 1D).
Exosomes derived from hucMSCs improved renal function
and ameliorated morphology in cisplatin-induced AKI rats
At 2 days after cisplatin injection, we observed a signifi-
cant rise in BUN and Cr levels in the PBS group and
Figure 2 (See legend on next page.)
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Figure 2 Exosomes released from human umbilical cord mesenchymal stem cells (hucMSCs) induced an accelerated acute kidney
injury (AKI) rat recovery. (A) Blood urea nitrogen (BUN) and creatinine (Cr) values from 0 days to 5 days. At 24 h after cisplatin administration,
rats received a renal capsule injection of 200 μg of exosomes from hucMSCs per kidney. Analysis of variance (ANOVA) with two-way classification
was performed: *P <0.001, phosphate-buffered saline (PBS) group vs normal group; #P <0.001, hucMSC-ex group vs PBS group. Results showed
that BUN and Cr levels were significantly lower in the hucMSC-ex group than in the PBS, hucMSC-CM, non-hucMSC-ex and human lung fibroblast
secreted exosomes (HFL-1-ex) groups from 3 days to 5 days. There were no marked changes in the PBS, hucMSC-CM, non-hucMSC-ex and HFL-1-ex
groups. (B) Representative micrographs of renal histology at day 5 in the four groups. There were numerous examples of necrosis of the proximal
epithelium and tubular protein casts in the PBS, hucMSC-CM, non-hucMSC-ex and HFL-1-ex groups, but this was not the case in the hucMSC-ex
group. Original magnification, × 200. Scale bars: 100 μm. Group, n = 6. (C) Incorporation of hucMSC-ex in tubular epithelial cells by renal capsule
injection: (a) unlabeled hucMSC-ex was injected into the kidney, no red fluorescence was detected; (b) red fluorescence (white arrows) was observed
in the tubular epithelial cells after injection of CM-Dil dye-labeled hucMSC-ex at 24 h. Tubular epithelial cell cytoplasm and nuclei were stained green
and blue, respectively. Original magnification × 200.
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clearly improved from day 3 to day 5 after the rats were
treated with hucMSC exosomes (P <0.001). However,
the BUN and Cr levels in the hucMSC-CM, non-
hucMSC-ex and HFL-1-ex groups had no notable
changes compared to the PBS group (Figure 2A).
Lesions were observed in rats with cisplatin injection at
day 5 by H&E staining of kidney tissue slices. The slices
showed that numerous necrotic areas of the proximal
epithelium had appeared and abundant tubular protein
casts had formed in the PBS, hucMSC-CM, non-
hucMSC-ex and HFL-1-ex groups. However, the tubular
lesions markedly decreased in the hucMSC-ex group
(Figure 2B). After CM-Dil-labeled hucMSC-ex was
injected at 24 h, red fluorescence was detected in the
tubular epithelial cells (Figure 2C(b)). The red fluores-
cence was not observed in unlabeled hucMSC-ex admin-
istration kidney samples (Figure 2C(a)).HucMSC-ex inhibited cisplatin-induced renal tubular
apoptosis and improved renal cell proliferation in rats
As shown in Figure 3A, renal tubular cell apoptosis
appeared in cisplatin-induced AKI rats, and hucMSC-ex
repressed apoptotic action and enhanced tubular cell pro-
liferation in the cisplatin-induced AKI model. The number
of TUNEL-positive cells significantly increased after cis-
platin treatment compared to the normal group, while the
kidneys of hucMSC-ex-treated rats subjected to cisplatin
exhibited less TUNEL-positive cells. Furthermore, AKI
rats treated with hucMSC-ex displayed a marked increase
in PCNA-positive cells compared to untreated AKI
rats (Figure 3A). The expression of Bax and Bcl-2 pro-
tein were observed by western blotting in kidney tis-
sues. The level of Bax was evidently raised in the PBS
group compared to the normal group. After treatment
with hucMSC-ex, its expression was reduced. Bcl-2 ex-
pression in the hucMSC-ex group was also reversed
(Figure 3B). The HFL-1-ex group showed similar re-
sults to the PBS group.HucMSC-ex depressed cisplatin-induced renal oxidative
stress in vivo and in vitro
The cisplatin-induced rat model of AKI is accompanied
by oxidative stress. In the cisplatin-treated group in vivo
and in vitro, the oxidative stress product 8-OHdG not-
ably increased, which decreased significantly in the
hucMSC-ex-treated group (Figures 4A and 5A). 8-
OHdG-positive cells were counted in ten consecutive
fields in the sections. This showed that the level of 8-
OHdG was higher in the cisplatin and HFL-1-ex groups
than in the hucMSC-ex group (P <0.001) (Figures 4B
and 5B). The GSH levels were reduced, and the levels of
MDA remarkably enhanced in the cisplatin-treated
group compared to the normal group. When comparing
the hucMSC-ex-treated group with the PBS and cisplatin
groups, the levels of GSH (P <0.01) were clearly in-
creased, while the MDA levels (P <0.001) decreased
(Figures 4C and 5C). Western blot results suggested that
cisplatin-induced oxidative stress activated the p38MAPK
pathway, which was suppressed by hucMSC-ex. The acti-
vated p38MAPK pathway could lead to caspase 3 expres-
sion, but it was inhibited after hucMSC-ex treatment.
The HFL-1-ex group had no significant changes com-
pared to the PBS and cisplatin groups in vivo and
in vitro (Figures 4D and 5D).HucMSC-ex suppressed cisplatin-induced apoptosis and
promoted proliferation in NRK-52E cells
Treatment with cisplatin and cisplatin plus HFL-1-ex
resulted in an increase in green fluorescence and a re-
duction in red fluorescence compared to NRK-52E cells
without cisplatin treatment (control group); the ratio of
green to red fluorescence ratio increased correlating
with an increase in mitochondrial membrane potential.
It indicated that NRK-52E cells generated early apoptosis
by treatment of cisplatin. After treatment with hucMSC-
ex, the ratio of green to red fluorescence was reduced,
suggesting the number of apoptosis cells decreased
(Figure 6A). The expression of apoptosis-associated
Figure 3 Human umbilical cord mesenchymal stem cell (hucMSC) exosomes suppressed renal cell apoptosis and promoted renal cell
proliferation in cisplatin-induced acute kidney injury (AKI) rats. (A) Representative images of terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nick-end labeling (TUNEL)-positive cells notably increased in the phosphate-buffered saline (PBS) and human lung fibroblast secreted
exosomes (HFL-1-ex) groups compared to the hucMSC-ex group, while proliferating cell nuclear antigen (PCNA)-positive cells were clearly more
numerous in the hucMSCs-ex group than the PBS and HFL-1-ex groups. Original magnification, × 200, Scale bars: 100 μm. (B) Western blot
analysis of B cell lymphoma 2 (Bcl-2) protein and Bcl-2-associated X protein levels in the kidney tissues showed that Bax expression increased
while the expression of Bcl-2 was reduced in the PBS and HFL-1-ex groups. This phenomenon was reversed in hucMSC-ex-treated group.
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ting. The level of Bax was seemingly higher in the cis-
platin group than the control group, but after
treatment with hucMSC-ex its expression decreased. In
the cisplatin group, the expression of Bcl-2 was lower
than the control group. However, it was increased by
treatment of hucMSC-ex (Figure 6B). Western blot
analyses also showed that PCNA and phosphorylated-
ERK expression decreased markedly in the cisplatin
group, which indicated that the cell proliferation ability
was obviously weakened. The incubation of cisplatin-
treated NRK-52E cells with hucMSC-ex caused higher
level of PCNA and p-ERK. There was no evident alter-
ation in the HFL-1-ex group compared to the cisplatin
group (Figure 6C).
In order to determine the mechanism of hucMSC-ex
action in promoting cell proliferation, we added
mitogen-activated protein kinase kinase (MEK) inhibitor
to hucMSC-ex-treated NRK-52E cells. Western blot re-
sults showed that p-ERK was markedly increased in thehucMSC-ex group compared to the cisplatin group; this
phenomenon was inhibited by U0126 and the PCNA ex-
pression was also suppressed subsequently (Figure 6D).
Discussion
Our laboratory has previously demonstrated that MSCs de-
rived from human umbilical cords could repair ischemia/
reperfusion-induced AKI [5,6], but the exact mechanism
is unclear. Therefore, we considered whether the effect of
hucMSCs on AKI rats was via a paracrine secretion me-
chanism. At the same time, recent studies have showed
that nephrotoxicity induced by cisplatin is mainly caused
by oxidative stress damage inducing renal tubular epithe-
lial cell apoptosis [22,25]. Based on these findings, in the
present study we demonstrated that exosomes released by
hucMSCs can ameliorate cisplatin-induced acute kidney
injury by antioxidation and antiapoptosis actions and pro-
motion of cell proliferation.
Exosomes are 40 to 100 nm in size and spheroid in
shape, and are secreted by various cells. They contain
Figure 4 Human umbilical cord mesenchymal stem cell (hucMSC) exosomes attenuated tubular oxidative damage in cisplatin-induced
acute kidney injury (AKI) rats. (A) Immunohistochemistry was used to detect the oxidative stress marker 8-hydroxy-2′-deoxyguanosine
(8-OHdG). The number of 8-OHdG-positive cells decreased in hucMSC-ex-treated rats compared to untreated rats. Original magnification, × 200,
Scale bars: 100 μm. (B) Quantitative analysis of 8-OHdG-positive cells indicated that hucMSC-ex reduced cisplatin-induced kidney oxidative
damage. Analysis of variance (ANOVA) was performed with the Student-Newman-Keuls multicomparison test. ***P <0.001. (C) Glutathione (GSH)
and malondialdehyde (MDA) levels were examined in kidney tissue homogenates with the respective detection kits (see Methods). GSH
expression was reduced, while MDA content increased in the phosphate-buffered saline (PBS) and human lung fibroblast secreted exosomes
(HFL-1-ex) groups, but this phenomenon was reversed in the hucMSC-ex group. ANOVA was performed with the Student-Newman-Keuls
multicomparison test. **P <0.01, ***P <0.001. (D) Western blot analysis showed that the expression of p-p38 and caspase 3 was higher in the PBS
and HFL-1-ex group, while it was suppressed by hucMSC-ex. It indicated that hucMSC-ex inhibited activation of p38 mitogen-activated protein kinase
(p38MAPK) by cisplatin-induced oxidative stress and suppressed p38MAPK induced caspase 3 expression, thereby decreasing cell apoptosis.
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cation between cells [14-16]. It has been reported that
CD9, CD63, and CD81 are located frequently on the sur-
face of exosomes [17]. The exosomes we obtained from
hucMSCs and HFL-1 had the same characteristics:
transmission electron microscopy showed a spheroid
morphology and confirmed their size of 40 to 100 nm,
and western blotting analyses showed they were positive
CD9, CD63, and CD81 expression. Therefore, they were
used in the experiment.
In the present study, we observed that exosomes could
become incorporated into the injured tubular epithelial
cells, thus accelerating the functional and morphologic
recovery of AKI induced by cisplatin. After administra-
tion of hucMSC-ex, the level of BUN and Cr was signifi-
cantly limited, and necrosis of proximal epithelium and
abundant tubular protein casts were reduced comparedto the PBS, hucMSC-CM, non-hucMSC-ex and HFL-ex
groups. It was suggested that cisplatin-induced AKI was
associated with a rise in the proapoptotic protein Bax
and a reduction in the antiapoptotic protein Bcl-2 [26].
In our study, the hucMSC-ex group had an evident de-
crease in Bax compared to the cisplatin alone treatment
group, while Bcl-2 protein increased after treating with
hucMSC-ex in vivo and in vitro. In addition, the number
of apoptotic cells was markedly increased in the PBS
group, while it was reduced by hucMSC-ex in vivo.
Mitochondrial membrane potential detection was used
for cell early apoptosis; the ratio of green to red fluores-
cence increased correlating with an increase in mitochon-
drial depolarization, which means that cells are exposed to
apoptosis [27]. We demonstrated that the ratio of green to
red fluorescence was higher in cisplatin-treated NRK-52E
cells than controls, and it was reduced by hucMSC-ex.
Figure 5 Human umbilical cord mesenchymal stem cell (hucMSC) exosomes depressed cisplatin-induced NRK-52E cell oxidative
damage in vitro. (A) Immunohistochemistry was used to measure levels of the oxidative stress marker 8-hydroxy-2′-deoxyguanosine (8-OHdG).
The number of 8-OHdG-positive cells was raised in the cisplatin and human lung fibroblast secreted exosomes (HFL-1-ex) groups compared to
the control group, which was reduced by hucMSCs-ex. Original magnification, × 200, Scale bars: 100 μm. (B) Quantitative analysis of 8-OHdG-positive
cells indicated that hucMSC-ex inhibited cisplatin-induced NRK-52E cell oxidative damage. Analysis of variance (ANOVA) was performed with the
Student-Newman-Keuls multicomparison test. ***P <0.001. (C) Glutathione (GSH) and malondialdehyde (MDA) levels were examined in cell
homogenates. GSH levels decreased and MDA levels increased in the cisplatin and HFL-1-ex groups; this was reversed in hucMSC-ex. ANOVA was
performed with the Student-Newman-Keuls multicomparison test. **P <0.01, ***P <0.001. (D) Western blot results showed that p-p38 and caspase 3
expression were lower in the hucMSC-ex group than in the cisplatin and HFL-1-ex groups, which demonstrated that hucMSC-ex suppressed activation
of p38 mitogen-activated protein kinase (p38MAPK) by cisplatin-induced oxidative stress and depressed the expression of caspase 3, which is
increased by p38MAPK.
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[11], but the mechanism is unclear. In this study, we
found that hucMSC-ex could activate ERK1/2 to pro-
mote damaged cell proliferation, and subsequently renal
injury repair. Expression of PCNA in the group treated
with hucMSC-ex significantly increased compared to the
PBS and cisplatin groups in vivo and in vitro. In order to
prove for definite cell proliferation was by activation of
the ERK1/2 pathway, in vitro, the MEK inhibitor U0126
and hucMSC-ex were added to cisplatin-induced NRK-
52E cells at the same time. Western blot analyses indi-
cated that after administration of U0126, p-ERK was
suppressed and the expression of PCNA was also de-
pressed. In addition, we also found that hucMSCs-ex
could reverse oxidative stress to repair the kidney injury.
Cisplatin-induced oxidative stress was considered to
be the main reason for AKI occurrence. Oxidative stress
leads to lipid peroxidation and thereby formation of theharmful product MDA [28], and induces DNA oxidative
damage accordingly via generation of 8-OHdG [29].
Meanwhile, the activity of antioxidant defense enzymes
is decreased [30], which leads to cell damage. These
cause the change in the oxidative stress markers: antioxi-
dant enzyme GSH levels were reduced, MDA expression
increased and 8-OHdG generated. In the current study,
it was observed that hucMSC-released exosomes had an
antioxidant role. MDA and 8-OHdG markedly increased
in the cisplatin-treated group in vivo and in vitro, while
it was reduced by hucMSC-ex. GSH content significantly
increased in the hucMSC-ex-treated group compared to
the cisplatin-treated group in vivo and in vitro. It has
already been reported that cisplatin-induced toxicity is
closely associated with ROS generated by cisplatin,
which leads to oxidative stress [31]. This activates
MAPK kinases 3, 4 and 6, which ultimately leads to the
activation of p38MAPK. The activated p38MAPK can
Figure 6 Exosomes released from human umbilical cord mesenchymal stem cells (hucMSCs) inhibited cisplatin-induced apoptosis and
promoted proliferation in NRK-52E cells. (A) Mitochondrial membrane potentials were analyzed to evaluate cell early apoptosis. The ratio of
green to red fluorescence was higher in the cisplatin and human lung fibroblast secreted exosomes (HFL-1-ex) groups than untreated NRK-52E
cells, suggesting early apoptosis of cells. The ratio was reversed after treating with hucMSC-ex in cisplatin-induced NRK-52E cells. Original
magnification, × 200. (B) Western blot analysis of B cell lymphoma 2 (Bcl-2) protein and Bcl-2-associated X protein (Bax) levels in NRK-52E cells:
Bax expression was raised in the phosphate-buffered saline (PBS) and HFL-1-ex groups compared to the control group, and this was reversed in
the hucMSC-ex group. The expression pattern for Bcl-2 was also reversed in the hucMSC-ex group. (C) Western blot results indicated increased
phosphorylated extracellular-signal-regulated kinase (p-ERK) expression in the hucMSC-ex group compared to the cisplatin and HFL-1-ex groups,
correlating with raised proliferating cell nuclear antigen (PCNA) expression. (D) HucMSC-ex and U0126 were added into the medium of cisplatin-
treated NRK-52E cells at the same time; p-ERK and PCNA expression were suppressed, as shown by western blot. This indicates that hucMSC-ex
promoted injured NRK-52E cell proliferation by activation of the ERK1/2 pathway.
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tosis [20,32,33]. In this study, we indicate that the
cisplatin-treated group had higher p-p38 and caspase 3
levels compared to the control group, while this was
significantly reduced after treatment with hucMSC-ex
compared to the cisplatin-treated group in vivo and
in vitro. These results further support the involvement
of oxidative stress in cisplatin-induced nephrotoxicity. It
is a foundation for clinical treatment of cisplatin-
induced acute renal injury.
The precise mechanism of how hucMSC-derived
exosomes repair cisplatin-induced AKI is still unclear,
but it can be concluded from the results of the present
study that hucMSC-ex could be resistant to cisplatin-
induced kidney oxidative stress, renal cell apoptosis and
promote cell proliferation, thus ameliorating cisplatin-
induced acute kidney injury. However, in the above re-
sults there were no marked changes when comparing
the cisplatin-treated group in vivo and in vitro to the
HFL-1-ex group.
Conclusions
As is well known, cisplatin treatment results in pro-
nounced kidney oxidative stress and renal cell apoptosis
in vivo and in vitro. Based on the present study, the fol-
lowing conclusions may be drawn: firstly, hucMSC-
excreted exosomes can resist cisplatin-induced oxidative
stress by reducing formation of some harmful products
(8-OHdG, MDA), increasing GSH levels and suppressing
activation of the p38MAPK pathway. Secondly, treat-
ment with hucMSC-ex reduced the apoptosis of cells
caused by oxidative stress and other reasons, and pro-
moted cell proliferation through activation of ERK1/2.
In summary, hucMSC-ex could ameliorate cisplatin-
induced nephrotoxicity and could be exploited as a new
therapeutic tool for regenerative medicine.
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